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Background: Recent published data on pneumococ-
cal vaccination coverages among adults are scarce. 
Aim: To update on pneumococcal vaccination uptakes 
among middle-aged and older adults in Catalonia. 
Methods: We conducted a population-based retro-
spective observational study including 2,057,656 
individuals ≥ 50 years old assigned to primary care cen-
tres managed by the Catalonian Health Institute on 1 
January 2017 (date of data collection). An institutional 
clinical research database (SIDIAP) was used to clas-
sify persons by vaccination status for both 23-valent 
pneumococcal polysaccharide (PPsV23) and 13-valent 
pneumococcal conjugate (PCV13) vaccines, as well as 
to identify underlying risk conditions. Results: Overall, 
796,879 individuals (38.7%) had received PPsV23 and 
13,607 (0.7%) PCV13. PPsV23 coverage increased with 
age: 9.2% (95,409/1,039,872) in 50–64 year olds, 
63.1% (434,408/688,786) in 65–79 year olds and 81.2% 
(267,062/328,998) in ≥ 80 year olds (p < 0.001). PCV13 
coverage also increased with age, although percent-
ages were smaller in all age strata (4,250/1,039,872: 
0.4%; 6,005/688,786: 0.9% and 3,352/328,998: 1.0%, 
respectively; p < 0.001). By sex, no substantial cover-
age differences were observed. Considering publi-
cally funded target groups for PPsV23 vaccination 
in Catalonia (i.e. < 65 year olds with at least one risk 
factor, plus all adults aged ≥ 65 years), PPsV23 cover-
age reached 52.8% (771,722/1,462,261) in our study 
population. Regarding PCV13 publicly funded targets 
(i.e. all-age immunocompromised persons), PCV13 cov-
erage was 3.3% (6,617/202,348). By risk conditions, 
the highest PPsV23 coverage appeared in congestive 
heart failure (51,909/63,596; 81.6%), chronic renal dis-
ease (122,791/158,726; 77.4%) and chronic bronchitis/
emphysema (96,453/132,306; 72.9%). Maximum PCV13 
coverage appeared in cirrhosis (294/7,957; 3.7%), 
chronic renal disease (5,633/158,726; 3.5%) and 
chronic bronchitis/emphysema (2,859/132,306; 2.2%). 
Conclusion: Pneumococcal vaccination coverages 
in Catalonian adults are suboptimal, especially for 
PCV13.
Introduction
Infections caused by  Streptococcus pneumoniae  are 
an important cause of morbidity and mortality around 
the world [1]. At present, two pneumococcal vaccines, 
the classical 23-valent pneumococcal polysaccharide 
vaccine (PPsV23) and the new 13-valent pneumococcal 
conjugate vaccine (PCV13), are available for using in at-
risk individuals and older adults [2,3].
In the United States (US), a leading setting on pneumo-
coccal vaccination in adults, the Healthy People 2020 
goals include to increase pneumococcal vaccination 
coverages to 60% in high-risk adults aged 18–64 years 
and to 90% in all people aged ≥ 65 years [4]. However, 
few recent coverage data (i.e. after PCV13 approval for 
adults in 2012) are available [5-7]. Updated data on both 
PPsV23 and PCV13 vaccination coverages in adults are 
therefore needed, especially now that pneumococcal 
vaccination programmes for adults and children are 
routinely implemented in many settings. Moreover, 
these data are also relevant to evaluate direct and 
indirect protective effects (e.g. herd protection) on the 
population [8].
In Catalonia, similar to the rest of Spain, PPsV23 is 
publicly funded since the 2000s for all individuals aged 
≥ 65 years (with or without risk conditions) and for indi-
viduals 18–64 years old with certain at-risk conditions 
(i.e. immunocompromising conditions, chronic pul-
monary/respiratory diseases, heart diseases, chronic 
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renal disease, diabetes mellitus, cirrhosis, alcohol-
ism and/or smoking). PPsV23 revaccination is recom-
mended and publicly funded for those persons who 
received a prime dose before 65 years of age [9]. Since 
2012 the PCV13 is publicly funded only for some indi-
viduals at high risk (mainly immunocompromised per-
sons). The PCV13 is also prescribed by some clinicians 
for patients with certain at-risk conditions (i.e. chronic 
bronchitis, asthma, cardiac diseases, etc.) although it 
is not publicly funded for these patients [9,10].
This study reports current pneumococcal vaccination 
uptakes for both PPsV23 and PCV13 vaccines among 
the general adult population ≥ 50 years old in Catalonia 
in January 2017, assessing vaccine coverages by age, 
sex and presence of major underlying risk conditions.
Methods
Study type
This is a population-based retrospective observational 
study involving 2,057,656 individuals aged ≥ 50 years, 
who constituted all persons registered in the primary 
care centres (PCCs) managed by the Catalonian Health 
Institute (ICS, Institut Català de la Salut) in Catalonia 
on 1 January 2017 (date of the study).
Ethical statement
The study was approved by the ethical committee of 
the institution (file P14/134) and was conducted in 
accordance with the general principles for observa-
tional studies [11].
Setting and study population
In Catalonia, similar to the rest of Spain, a compulsory 
health insurance system by the National Health Service 
covers all inhabitants’ medical needs and all inhabit-
ants are assigned to a PCC. In Catalonia there are 358 
PCCs, including 274 (76.5%) managed by the ICS and 
84 by other providers. The study population assigned 
to the 274 PCCs managed by the ICS (n = 2,057,656 per-
sons aged ≥ 50 years) represents a 76.3% of the total 
2,693,570 Catalonian inhabitants in this age strata [12].
In all PCCs, doctors and nurses systematically use elec-
tronic medical records to record diagnoses, prescrip-
tions, vaccinations and patient management activities 
coded according to the International Classification of 
Diseases, 10th Revision (ICD-10) [13].
Data sources
The Catalonian Health Institute Information System for 
the Development of Research in Primary Care (SIDIAP 
research database), which compiles coded clinical 
information from the electronic medical records of the 
274 PCCs managed by the ICS, was used as main data 
source for this report [14]. The SIDIAP sample is rep-
resentative of the general Catalan population in terms 
of geographical, age and sex distributions according to 
census data [12], and its utility for clinical research has 
been previously reported [15]. In 2012, the US Food and 
Drug Administration (FDA) and the European Medicines 
Agency (EMA) approved PCV13 use in adults  ≥ 50 years 
old [16,17]. Subsequently, information on pneumococ-
cal vaccination with this vaccine for this age group was 
recorded in the SIDIAP research database. Vaccination 
with PPsv23 is recorded since 1999.
The SIDIAP research database was used to classify 
study persons by their pneumococcal vaccination sta-
tus as well as to identify comorbidities and underlying 
risk conditions in each individual. The following risk 
conditions were defined on the basis of ICD-10 codes 
registered in the electronic PCCs medical records con-
tained in the SIDIAP research database: asthma (J45–
J46), chronic bronchitis/emphysema (J41–J44), chronic 
renal disease (N18–N19), congestive heart failure (I50), 
coronary artery disease (I20–I22, I25), diabetes mel-
litus (E10–E14), liver cirrhosis (K74), solid organ or 
haematological neoplasia (C00–C97), as well as alco-
holism (F10, G31.2, G62.1, G72.1, I42.6, K29.2, K70) and 
current smoking (F17). We considered healthy (immu-
nocompetent persons without risk conditions), at-risk 
(immunocompetent persons with any risk condition) 
and high-risk (immunocompromised persons) groups. 
Immunocompromisation was considered as a compos-
ite variable defined by the presence of any of the fol-
lowing: HIV infection, immunodeficiency, severe renal 
disease, solid organ or haematological neoplasia and/
or immunosuppressive treatment.
Review of vaccination status
Pneumococcal vaccination status for PPsV23 and PCV13 
was determined by reviewing the electronic PCCs clini-
cal records of the SIDIAP database, which contain spe-
cially designated fields for both PCV13 and PPsV23 
pneumococcal vaccinations (virtually all of them are 
administered at the PCCs in the Spanish healthcare 
system). We assumed that information in electronic 
clinical records was complete, so a person was con-
sidered as unvaccinated when a vaccination was not 
recorded. Persons were considered vaccinated against 
pneumococcus if they had received at least one dose of 
PPsV23 or PCV13.
Data analysis
Vaccination coverage for both PPsV23 and PCV13 was 
estimated by age strata, sex and presence of at-risk 
conditions. The chi-squared test was used to compare 
proportions of PPSV23/PCV13 vaccinated vs non-vac-
cinated in the initial univariate analyses. Unadjusted 
odds ratios (ORs) were calculated to estimate the 
probability of vaccination according to each one of 
the studied covariables (age strata, sex and presence 
of distinct risk conditions). We did logistic regression 
analyses (with the ‘enter’ method including all covaria-
bles with a significance level p < 0.10 in previous univar-
iate analyses) to calculate multivariable-adjusted ORs 
for vaccination (PPSV23 and/or PCV13) [18]. Statistical 
significance was set at p < 0.05 (two-tailed). Data were 
analysed by using IBM SPSS Statistics for Windows, 
version 24 (IBM Corp., Armonk, New York, US).
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Results
The studied population included 2,057,656 persons, 
of whom 950,042 (46.2%) were men and 1,107,614 
(53.8%) were women. By age strata, 1,039,872 (50.5%) 
were aged 50–64 years, 688,786 (33.5%) were aged 
65–79 years and 328,998 (16.0%) were aged ≥ 80 years.
Considering chronic respiratory diseases, 132,306 
study persons (6.4%) had chronic bronchitis/emphy-
sema and 95,600 (4.6%) had asthma. Considering 
other at-risk conditions, 350,511 study persons (17.0%) 
had diabetes mellitus, 344,471 (16.7%) were current 
smokers, 236,623 (11.5%) had cancer, 158,726 (7.7%) 
chronic renal disease, 117,575 (5.7%) coronary artery 
disease, 63,596 (3.1%) congestive heart failure, 64,829 
(3.2%) abused alcohol and 7,957 (0.4%) had cirrhosis.
Overall, 796,879 persons (38.7%) had received PPsV23 
at any time (186,242 vaccinated within the last 5 years) 
and 13,607 (0.7%) had received PCV13 (all of them 
within the previous 5 years). Of the 796,879 PPsV23 
vaccinated persons, 121,595 had received two doses 
and 2,347 received three or more doses. Of the 13,607 
PCV13 vaccinated persons, 148 had received two doses 
and 60 received three doses.  Table 1  shows both 
PPSV23 and PCV13 pneumococcal vaccination cover-
ages by sex and age strata. PPsV23 coverage largely 
increased with increasing age (9.2% in 50–64 years vs 
63.1% in 65–79 years vs 81.2% in ≥ 80 years; p < 0.001) 
and was slightly lower in men than in women (37.4% 
vs 39.9%; p < 0.001). PCV13 coverage also increased 
with age, although it was very low in all age groups 
(0.4% in 50–64 years vs 0.9% in 65–79 years vs 1.0% 
in ≥ 80 years; p < 0.001) and was slightly greater in men 
than in women (0.8% vs 0.6%; p < 0.001).
Table 2 shows pneumococcal vaccination coverages by 
underlying risk conditions. The highest PPsV23 cov-
erage was observed among persons with congestive 
heart failure (81.6%) followed by chronic renal dis-
ease (77.4%), chronic bronchitis/emphysema (72.9%) 
and coronary artery disease (69.3%). Maximum PCV13 
coverage was observed among patients with cirrho-
sis (3.7%) followed by chronic renal disease (3.5%), 
chronic bronchitis/emphysema (2.2%) and congestive 
heart failure (2.1%). The lowest PPsV23 coverage was 
observed among patients who abused alcohol (35.5%) 
and smoked (20.0%). Similarly, the lowest PCV13 
Table 1
Pneumococal vaccination coverages with PPsV23 and PCV13 by sex and age strata, Catalonia, Spain, 2017 (n = 2,057,656)
Characteristic
PPsV23 PCV13
n % n %
Aged 50–64 years
Men (n = 512,108) 51,120 10 2,409 0.5
Women (n = 527,764) 44,289 8.4 1,841 0.3
All (n = 1,039,872) 95,409 9.2 4,250 0.4
Aged 65–79 years
Men (n = 316,831) 203,020 64.1 3,430 1.1
Women (n = 371,955) 231,388 62.2 2,575 0.7
All (n = 688,786) 434,408 63.1 6,005 0.9
Aged ≥ 80 years
Men (n = 121,103) 101,199 83.6 1,637 1.4
Women (n = 207,895) 165,863 79.8 1,715 0.8
All (n = 328,998) 267,062 81.2 3,352 1.0
All-age groups
Men (n = 950,042) 355,339 37.4 7,476 0.8
Women (n = 1,107,614) 441,540 39.9 6,131 0.6
Overall (n = 2,057,656) 796,879 38.7 13,607 0.7
PPsV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.
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coverage was also observed in people who smoke 
(0.5%) or abuse alcohol (0.7%).
Table 3  shows distinct pneumococcal vaccine cover-
ages (PPsV23, PCV13, dual vaccination, any vaccine) 
according to age subgroups (50–64 years, ≥ 65 years) 
and risk strata (healthy, at-risk and high-risk/immu-
nocompromised) in the study population. Considering 
exclusively persons who had any type of risk condition, 
the proportion vaccinated with any vaccine was 16.1% 
(71,495/444,477) among those aged < 65 years and 
76.4% (426,429/558,070) among those aged ≥ 65 years. 
Considering target groups where PPsV23 is recom-
mended and publicly funded in Catalonia (i.e. all adults 
who are either < 65 years old with at least one risk fac-
tor plus all adults ≥ 65 years), PPsV23 coverage reached 
52.8% (771,722/1,462,261). Considering exclusively 
persons for whom PCV13 is publicly funded in our set-
ting (i.e. all-age immunocompromised/high-risk per-
sons), PCV13 coverage was 3.3% (6,617/202,348).
Tables 4  and  5  show unadjusted and multivariable-
adjusted analysis estimating ORs for PPsV23 and 
PCV13 vaccinations considering the distinct study 
covariables. In the multivariable analysis, age was the 
strongest predictor for PPsV23 vaccination. If we con-
sider PCV13, the strongest predictor for vaccination 
was the presence of chronic renal disease (OR: 7.49; 
95% CI: 7.19–7.79), followed by cirrhosis (OR: 4.21; 
95% CI: 3.72–4.76) and chronic bronchitis/emphysema 
(OR: 2.54; 95% CI: 2.43–2.66). 
Discussion
Pneumococcal vaccination (including both PPsV23 and 
PCV13) is commonly recommended for individuals at 
risk or at high risk and older adults [2,3]. However, 
there is scarce available data about pneumococcal vac-
cination coverages among adults in recent years (after 
PCV13 licensure) and information on pneumococcal 
vaccination uptake is not routinely available.
The present large population-based study, involv-
ing more than 2 million persons ≥ 50 years old in 
Catalonia, shows an overall vaccination uptake of 
approximately 39% for the classical PPsV23 and 1% 
for the new PCV13 in January 2017. As compared with 
a prior study that evaluated vaccination coverages in 
Catalonia in January 2015 [7], current PPsV23 uptake 
is essentially similar (38.8% (789,098/2,033,465) in 
2015 vs 38.7% (796,879/2,057,657) in 2017, p = 0.105) 
whereas PCV13 uptake, while very low, has slightly 
increased (from 0.2% (5,031/2,033,465) in 2015 to 
0.7% (13,607/2,057,657) in 2017, p < 0.001).
Our global pneumococcal vaccination coverage seems 
to be so far from the Healthy People 2020 goals (60% 
Table 2




n % n %
Chronic respiratory diseases
Chronic bronchitis/emphysema (n = 132,306) 96,453 72.9 2,859 2.2
Asthma (n = 95,600) 52,817 55.2 1,218 1.3
Chronic heart diseases
Congestive heart failure (n = 63,596) 51,909 81.6 1,327 2.1
Coronary artery disease (n = 117,575) 81,491 69.3 715 0.6
Diabetes mellitus (n = 350,511) 242,214 69.1 4,179 1.2
Chronic renal disease (n = 158,726) 122,791 77.4 5633 3.5
Cirrhosis (n = 7,957) 4,576 57.5 294 3.7
Cancer (n = 236,623) 139,911 59.1 3,758 1.6
Alcoholism (n = 64,829) 22,992 35.5 492 0.7
Smoking (n = 344,471) 68,966 20.0 1,646 0.5
Splenectomy (n = 362) 190 52.5 92 25.4
PPsV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.
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for at-risk adults aged < 65 years and 90% for elderly 
people) [4], but it must be noted that this global vac-
cination coverage is estimated considering the total 
population aged ≥ 50 years. Coverage rates are consid-
erably greater when younger persons in this population 
(i.e. aged < 65 years) without underlying risk condi-
tions are excluded in the analyses. Indeed, some spe-
cific population subgroups in this study have PPsV23 
uptakes near to the Healthy People 2020 goal. If we 
consider exclusively elderly people, (i.e. ≥ 65 years), 
the observed PPsV23 coverage was 63.1% among 
persons 65–79 years and reached 81.2% among per-
sons ≥ 80 years old. Similarly, high PPsV23 coverage 
emerged among persons with cardiac diseases (81.6% 
in congestive heart failure and 69.3% in coronary artery 
disease), chronic renal disease (77.4%) and chronic 
bronchitis/emphysema (72.9%).
If we consider PCV13, the global vaccine uptake 
remains very low in our setting at the beginning of 2017, 
despite being approved for use in adults since 2012 
[3]. The lack of public funding in our setting (funded 
only for immunocompromised persons), together with 
its greater price and lower serotype-coverage than the 
classical PPsV23, could explain, in part, the very low 
PCV13 uptakes observed in our population.
Since pneumococcus is a major cause of morbidity 
and mortality in high-risk adults and elderly people, 
routine vaccination against pneumococcal diseases 
is recommended for these persons in many countries 
(although national guidelines differ, recommending 
either the PPsV23, the PCV13 or both). The classi-
cal PPsV23 offers 40–60% efficacy against invasive 
pneumococcal disease but its clinical effectiveness 
against pneumonia is uncertain [2]. The new PCV13 
has better immunogenicity than the polysaccharide 
vaccine and has a demonstrated 45% effectiveness 
against vaccine-type pneumococcal pneumonia, but it 
has lower serotype-coverage than the PPsV23 [3,19]. 
The lowest vaccination coverages for both PPsV23 and 
PCV13 in this study were observed among people who 
smoked and people who abused alcohol. Both are at-
increased risk to suffer pneumococcal infections and, 
Table 3
Pneumococcal vaccination coverages with PPsV23, PCV13, dual vaccination, or any vaccine, by age subgroups and risk 
strata among adults aged over 50 years, Catalonia, Spain, 2017 (n = 2,057,656)
Age groups
PPsV23 PCV13 PCV13 + PPsV23 PCV13 or PPsV23
n % n % n % n %
Aged 50–64  years
Healthy (n = 595,395) 25,157 4.2 705 0.1 300 0.1 25,562 4.3
At-riska (n = 385,743) 58,318 15.1 1,097 0.3 615 0.2 58,800 15.2
High-riskb (n = 58,734) 11,934 20.3 2,448 4.2 1,687 2.9 12,695 21.6
All (n = 1,039,872) 95,409 9.2 4,250 0.4 2,602 0.3 97,057 9.3
Aged ≥ 65  years
Healthy (n = 459,714) 275,700 60.0 1,607 0.3 1,371 0.3 275,936 60.0
At-riska (n = 414,456) 315,897 76.2 3,581 0.9 3,298 0.8 316,180 76.3
High-riskb (n = 143,614) 109,873 76.5 4,169 2.9 3,793 2.6 110,249 76.8
All (n = 1,017,784) 701,470 68.9 9,357 0.9 8,462 0.8 702,365 69.0
Overall (≥ 50  years)
Healthy (n = 1,055,109) 300,857 28.5 2,312 0.2 1,671 0.2 301,498 28.6
At-riska (n = 800,199) 374,215 46.8 4,678 0.6 3,913 0.5 374,980 46.9
High-riskb (n = 202,348) 121,807 60.2 6,617 3.3 5,480 2.7 122,944 60.8
All (n = 2,057,656) 796,879 38.7 13,607 0.7 11,064 0.5 799,422 38.9
PPsV23: 23-valent pneumococcal polysaccharide vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.
a Individuals considered at risk include immunocompetent persons with any of the following conditions: immunocompromising conditions, 
chronic pulmonary/respiratory diseases, heart diseases, chronic renal disease, diabetes mellitus, cirrhosis, alcoholism and/or smoking.
b Individuals considered at high risk are immunocompromised persons.
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consequently, vaccination uptakes should be largely 
improved in these groups. We underline the impor-
tance to continue public funding, especially among 
such target groups, to achieve reasonable vaccination 
uptakes. Barriers which limit vaccination uptake in 
these at-risk persons also require further investiga-
tion. In general, major factors related with vaccination 
acceptance in adults are self-perceived health and atti-
tudes (which could be an important barrier in people 
who abuse alcohol and/or smoke) as well as percep-
tions about mortality risk of the infectious disease and 
vaccine effectiveness [20]. We underline the key role of 
general practice doctors in recommending vaccination 
in these persons [21].
In our multivariable analyses, age was the strong-
est predictor for PPsV23 vaccination, whereas the 
presence of some underlying conditions (particularly 
chronic renal disease, cirrhosis and chronic bronchi-
tis/emphysema) was more predictive for PCV13 vac-
cination. These data fit with current pneumococcal 
vaccine recommendations in Catalonia, where PPSV23 
is recommended (and publicly funded) for all persons 
aged ≥ 65 years (with or without underlying conditions) 
whereas PCV13 is only publicly funded for persons with 
high-risk conditions [9].
In Europe, there is very scarce population-based data 
reporting pneumococcal vaccination coverages among 
adults [7,21-26], and vaccine uptakes are generally 
inferred from vaccine doses distributed [22]. According 
to available data, estimates of PPsV23 uptakes among 
older adults in Western European countries vary largely 
(between 8% and 69%), with greater uptakes in those 
countries with age-based recommendations and public 
funding/reimbursement [21-26].
Considering that PCV13 use for at-risk and older adults 
was approved a few years ago (2012), there is very 
scarce published data about PCV13 uptakes in adult 
populations [6,7]. Our data showing a global PCV13 
uptake less than one per cent (with maximum coverage 
Table 4
Unadjusted and multivariable-adjusted odds ratios for PPsV23 vaccination in adults, according to distinct study covariables, 
Catalonia, Spain, 2017 (n = 2,057,656))
Characteristic
Unadjusted Multivariable-adjusted
OR 95% CI p OR 95% CI p
Age
50–64 years (reference) 1.00 Reference
< 0.001
1.00 Reference
< 0.00165–79 years 16.91 16.77–17.05 14.21 14.09–14.34
≥ 80 years 42.68 42.22–43.16 30.63 30.27–31.00
Sex




Female 1.11 1.10–1.12 1.05 1.04–1.05
Chronic bronchitis/emphysema 4.71 4.66–4.76 < 0.001 3.64 3.58–3.71 < 0.001
Asthma 2.02 1.99–2.05 < 0.001 2.21 2.17–2.25 < 0.001
Congestive heart failure 7.45 7.30–7.60 < 0.001 1.51 1.48–1.55 < 0.001
Coronary artery disease 3.87 3.82–3.92 < 0.001 1.61 1.59–1.64 < 0.001
Diabetes mellitus 4.64 4.61–4.68 < 0.001 3.74 3.70–3.78 < 0.001
Cirrhosis 6.21 6.13–6.29 < 0.001 1.81 1.70–1.92 < 0.001
Chronic renal disease 2.15 2.05–2.25 < 0.001 1.61 1.58–1.63 < 0.001
Cancer 2.56 2.54–2.59 < 0.001 1.32 1.31–1.34 < 0.001
Alcoholism 0.87 0.85–0.88 < 0.001 1.15 1.12–1.18 < 0.001
Smoking 0.34 0.33–0.34 < 0.001 0.68 0.67–0.69 < 0.001
CI: confidence interval; OR: odds ratio; PPsV23: 23-valent pneumococcal polysaccharide vaccine.
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of 3.7% in liver cirrhosis) 5 years after its licensure, 
suggests that, apart from public funding/reimburse-
ment, risk-based vaccination strategies likely result in 
less vaccine uptake than age-based vaccination strat-
egies [22]. In the US, where PCV13 is recommended 
for all persons aged ≥ 65 years (with or without risk 
conditions) [27], a coverage of 31% has been recently 
reported [6].
Considering the possibility of a sequential use of PCV13 
plus PPsV23 (as recommended by the US Centers for 
Disease Control and Prevention for immunocompro-
mised/high-risk persons and elderly people) [3,27], 
only 2.7% of high-risk individuals (5,480/202,348) had 
received dual PCV13/PPsV23 vaccination in our setting. 
To date, recommendations for PPsV23 and PCV13 vac-
cination in adults are not uniform (varying between 
countries, scientific societies and clinical guidelines), 
with diversity in funding for PPsV23/PCV13 in distinct 
settings, which makes it difficult to achieve optimal 
vaccine uptakes and limits the comparability of cover-
age rates [9,10,27-30].
Considering PPsV23, we also note the difficulty to 
improve vaccination uptakes when the vaccine cover-
age is already relatively high. In fact, the reported 
PPsV23 uptakes among elderly individuals and specific 
comorbidity subgroups in Catalonia years ago were 
similar to PPsV23 uptakes observed currently [31].
Our study has several strengths. Design was popula-
tion-based and study population (which included more 
than 75% of the total Catalonian inhabitants ≥ 50 years) 
was representative and large enough to estimate 
accurately vaccination uptakes for both PPSV23 and 
PCV13 according to distinct age subgroups and specific 
underlying risk conditions. Quality criteria and utility 
of the SIDIAP research database (used to identify vac-
cinations, comorbidities and underlying risk conditions 
in the study population) have been previously reported 
Table 5
Unadjusted and multivariable-adjusted odds ratios for PCV13 vaccination in adults, according to distinct study covariables, 
Catalonia, Spain, 2017 (n = 2,057,656)
Characteristic
Unadjusted Multivariable-adjusted
OR 95% CI p OR 95% CI p
Age
50–64 years 1.00 Reference
< 0.001
1.00 Reference
< 0.00165–79 years 2.14 2.06–2.23 1.11 1.06–1.16






Female 0.70 0.68–0.73 0.81 0.78–0.84
Chronic bronchitis/emphysema 3.93 3.77–4.10 < 0.001 2.54 2.43–2.66 < 0.001
Asthma 2.03 1.91–2.16 < 0.001 1.83 1.72–1.94 < 0.001
Congestive heart failure 3.44 3.25–3.64 < 0.001 1.19 1.12–1.27 < 0.001
Coronary artery disease 2.40 2.28–2.53 < 0.001 1.14 1.08–1.21 < 0.001
Diabetes mellitus 2.17 2.10–2.25 < 0.001 1.30 1.25–1.35 < 0.001
Cirrhosis 8.73 8.43–9.03 < 0.001 4.21 3.72–4.76 < 0.001
Chronic renal disease 5.87 5.21–6.60 < 0.001 7.49 7.19–7.79 < 0.001
Cancer 2.97 2.86–3.08 < 0.001 2.13 2.04–2.21 < 0.001
Alcoholism 1.15 1.06–1.26 0.002 0.91 0.83–1.01 0.059
Smoking 0.68 0.65–0.72 < 0.001 0.80 0.76–0.85 < 0.001
CI: confidence interval; OR: odds ratio; PCV13: 13-valent pneumococcal conjugate vaccine.
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[15], and this database has been used as a reliable tool 
for epidemiological studies in our setting [7].
With regard to limitations of the study, we did not 
include people < 50 years old in our analyses. Moreover, 
for people aged ≥ 50 years, we assumed that informa-
tion in PCCs medical records was complete, but infor-
mation bias may have occurred if some comorbidities 
and/or vaccinations were not recorded. Concerning 
vaccination, while the utility of the SIDIAP database 
for clinical research has been previously described 
[15], there has not been any validation sub-study spe-
cifically focused on vaccination registries in the data-
base records. However possible bias/misclassification 
would likely be very small since almost all of adult vac-
cinations are administered in the PCCs in the Spanish 
Health System. Similarly, although it is possible that 
some comorbidities/chronic diseases (particularly 
in persons with mild symptoms or less frequency of 
attendance) were missed because a diagnosis code 
was not recorded, the possible misclassification would 
likely also be small considering that the observed 
prevalences fit with commonly reported prevalences 
for major comorbidities/risk conditions [32]. Patients 
attitudes, ethnicity and socio-economical information 
were not available in the present study, which may also 
be considered as a limitation given that disparities 
concerning these characteristics may influence pneu-
mococcal vaccination coverage according to previous 
studies [20,33].
In conclusion, the present large population-based 
study shows that approximately 39% of overall 
Catalonian people aged ≥ 50 years (with or without risk 
conditions) had received at least one dose of the clas-
sical PPsV23 as at January 2017, whereas less than 1% 
had received the new PCV13. By population subgroups, 
PPsV23 uptakes were higher in older persons (reaching 
81% among persons aged ≥ 80 years) and some sub-
groups with specific-comorbidities (81%, 77% and 73% 
among persons with cardiac, renal or pulmonary dis-
eases, respectively). In contrast, considering PCV13, 
maximum uptakes did not even reach 4% (even consid-
ering certain at-risk population subgroups).
We highlight the difficulties to compare pneumococ-
cal vaccination coverages in distinct countries due to 
the different characteristics of each national health 
service. Nevertheless, our study may provide valuable 
information for the evolution of pneumococcal vaccina-
tion coverage in a European region where PPsV23 is 
publicly funded for at-risk and high-risk adults and all 
elderly people whereas PCV13 is only publicly funded 
for high-risk individuals.
Recommendations for pneumococcal vaccination are 
currently heterogeneous depending on the distinct 
experts/clinical guidelines. To facilitate clinical prac-
tice and likely improve current vaccination coverage, 
more uniform recommendations (together with pub-
licly funded programmes) for PPsV23/PCV13 use would 
be needed. These should be age-based, risk-based 
or consensus-based and derived from updated data 
on efficacy, clinical effectiveness, epidemiological 
impact and cost-effectiveness for both PPsV23/PCV13 
in adults.
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